Silencing disease genes in the laboratory and the clinic
Synthetic nucleic acids are commonly used laboratory tools for modulating gene expression
and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs …
and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs …
Targeting RNA with small molecules—A safety perspective
HL Lightfoot, GF Smith - British Journal of Pharmacology, 2023 - Wiley Online Library
RNA is a major player in cellular function, and consequently can drive a number of disease
pathologies. Over the past several years, small molecule‐RNA targeting (smRNA targeting) …
pathologies. Over the past several years, small molecule‐RNA targeting (smRNA targeting) …
[HTML][HTML] Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic
Synthetic nucleic acids are commonly used laboratory tools for modulating gene expression
and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs …
and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs …
[HTML][HTML] Genome-wide analysis of pseudogenes reveals HBBP1's human-specific essentiality in erythropoiesis and implication in β-thalassemia
Y Ma, S Liu, J Gao, C Chen, X Zhang, H Yuan… - Developmental Cell, 2021 - cell.com
The human genome harbors 14,000 duplicated or retroposed pseudogenes. Given their
functionality as regulatory RNAs and low conservation, we hypothesized that pseudogenes …
functionality as regulatory RNAs and low conservation, we hypothesized that pseudogenes …
[HTML][HTML] Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
MC Palanca-Wessels, GC Booth, AJ Convertine… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The therapeutic potential of RNA interference (RNAi) has been limited by inefficient delivery
of short interfering RNA (siRNA). Tumor-specific recognition can be effectively achieved by …
of short interfering RNA (siRNA). Tumor-specific recognition can be effectively achieved by …
Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells
The application of small interfering RNA (siRNA) for cancer treatment is a promising strategy
currently being explored in early phase clinical trials. However, efficient systemic delivery …
currently being explored in early phase clinical trials. However, efficient systemic delivery …
N-methyl-D-aspartate receptors amplify activation and aggregation of human platelets
Background Glutamate is stored in platelet dense granules and large amounts (> 400 μM)
are released during thrombus formation. N-methyl-d-aspartate glutamate receptors …
are released during thrombus formation. N-methyl-d-aspartate glutamate receptors …
Links between the oncoprotein YB-1 and small non-coding RNAs in breast cancer
C Blenkiron, DG Hurley, S Fitzgerald, CG Print… - PloS one, 2013 - journals.plos.org
Background The nucleic acid-binding protein YB-1, a member of the cold-shock domain
protein family, has been implicated in the progression of breast cancer and is associated …
protein family, has been implicated in the progression of breast cancer and is associated …
A novel EGR‐1 dependent mechanism for YB‐1 modulation of paclitaxel response in a triple negative breast cancer cell line
Chemotherapy with taxanes such as paclitaxel (PTX) is a key component of triple negative
breast cancer (TNBC) treatment. PTX is used in combination with other drugs in both the …
breast cancer (TNBC) treatment. PTX is used in combination with other drugs in both the …
A novel β-glucan–oligonucleotide complex selectively delivers siRNA to APCs via Dectin-1
A Uno, K Arima, M Shimazaki, M Ushida… - Journal of Controlled …, 2021 - Elsevier
Delivering therapeutic nucleic acids to targeted cells and organs has been a challenge for
decades. A novel technology to deliver oligonucleotide therapeutics to immune cells is here …
decades. A novel technology to deliver oligonucleotide therapeutics to immune cells is here …